Global Rare Disease Diagnostics Market to 2025: Market was Valued $45.18 Billion in 2017 and is Anticipated to Reach $86.15 Billion

Dublin, Nov. 12, 2018 (GLOBE NEWSWIRE) -- The "Global Rare Disease Diagnostics Market: Focus on Genetic Diseases, Service Providers, Competitive Landscape, and Country - Analysis and Forecast, 2018-2025" report has been added to ResearchAndMarkets.com's offering.

The global rare disease diagnostics market was valued $45.18 billion in 2017 and is anticipated to reach $86.15 billion by 2025

Factors such as high incidence of rare diseases, presence of large numbers of research and development facilities for rare diseases, significant number of rare disease registries, high diagnosis rare of rare diseases in countries of North America, and extensive investments in different therapeutic areas are driving the growth of the North America rare disease diagnostics market. However, the Asia Pacific region is expected to register the highest CAGR of 9.22% during the forecast period 2018-2025.

Rare diseases, also known as orphan diseases, have become a major health burden in the recent times. Comprising 6000-7000 life threatening diseases, rare diseases affect small percentage of the population. Every country has their own definition of rare disease based on the country's population.

In the initial years, pharmaceutical companies were less interested in adopting them to develop treatments for such a small patient population, therefore the US FDA started giving orphan drug designations to the drug candidates intended to treat rare diseases. Orphan drug designations benefit companies from incentives for the development of these products until the marketing approval. The major challenge in rare diseases treatment is the lack of diagnosis, government policies, awareness and funding for R&D, along with long diagnostic delays.

The increasing patient pool for rare disease cancer, government funding to accelerate research in rare diseases, and interest of big pharmaceutical companies in manufacturing orphan drugs and orphan disease diagnostic devices are expected to be the major factors for the growth of the market.

Pharmaceutical giants such as Shire and Qiagen are investing in the R&D for the development of innovative and improved diagnostic devices and assays for rare disease. Rise in the awareness level among people on rare diseases is also expected to fuel the growth of the market. The rare disease has different definitions across different countries.

Key Topics Covered:

Executive Summary

1 Market Overview
1.1 Rare Disease Introduction
1.2 Tests Performed during Diagnosis
1.3 Rare Disease Challenges and Recommendations
1.4 List of Genetic Tests
1.5 Rare Disease Policies
1.6 A Path to Success: Partnerships and Coordinated Efforts of the Rare Diseases Community
1.7 Global Market Overview
1.8 Assumptions and Limitations

2 Market Dynamics
2.1 Market Dynamics: Drivers, Restraints, and Opportunities, and Trends
2.2 Rare Disease Diagnostics Market: Drivers
2.3 Rare Disease Diagnostics Market: Challenges
2.4 Rare Disease Diagnostics Market: Opportunity
2.5 Rare Disease Diagnostics Market: Trends

3 Competitive Landscape
3.1 Product Launches
3.2 Joint Venture, Collaborations, and Partnerships
3.3 IRDiRC Perspective: Progress in Rare Diseases Research, 2010-2016
3.4 Service Providers

4 Industry Insights
4.1 Funding Scenario
4.2 Legal Requirements and Regulations
4.3 List of Regulatory Bodies

5 Global Rare Disease Diagnostics Market (by Disease Type)
5.1 Key Takeaways
5.2 Rare Disease Market Attractiveness (by Disease Type)
5.3 Overview: Disease Type
5.4 Market Overview: Disease Type
5.5 Market Value (by Gastroenterology Disease Type), 2017-2025
5.6 Market Value ((by Endocrine and Metabolism Disorders Disease Type)), 2017-2025
5.7 Market Value (by Cardiovascular Disorders), 2017-2025
5.8 Market Value (by Neurology Disease Type), 2017-2025
5.9 Market Value (by Hematology and Oncology Disease Type), 2017-2025
5.10 Market Value (by Dermatology Disease Type), 2017-2025
5.11 Market Value (by Other Therapeutic Areas), 2017-2025

6 Global Rare Disease Diagnostics Market (by Test Type)
6.1 Key Takeaways
6.2 Rare Disease Market Attractiveness (by Test Type)
6.3 Overview: Test Type
6.4 Market Overview: Disease Type
6.5 Market Value (by Genetic Test Type), 2017-2025
6.6 Market Value (by General Lab Tests), 2017-2025
6.7 Market Value (by Imaging Test Type), 2017-2025
6.8 Market Value (by Other Tests), 2017-2025

7 Global Rare Disease Diagnostics Market (by Trait)
7.1 Key Takeaways
7.2 Rare Disease Market Attractiveness (by Trait Type)
7.3 Overview: Trait Type
7.4 Market Overview: Trait Type
7.5 Market Value (by Inherited Trait Type), 2017-2025
7.6 Market Value (by Acquired Trait Type), 2017-2025

8 Global Rare Disease Diagnostics Market (by Age Group)
8.1 Key Takeaways
8.2 Rare Disease Market Attractiveness (by Age Group)
8.3 Overview: Age Group
8.4 Market Overview: Age Group
8.5 Market Value (by Children Age Group), 2017-2025
8.6 Market Value (by Adult Age Group), 2017-2025

9 Global Rare Disease Diagnostics Market (by End User)
9.1 Key Takeaways
9.2 Rare Disease Market Attractiveness (by End User)
9.3 Market Overview: End User
9.4 Market Value (by Hospital Laboratories), 2017-2025
9.5 Market Value (by Diagnostic laboratories), 2017-2025
9.6 Market Value (by Genetic Testing Laboratories), 2017-2025
9.7 Market Value (by Cancer Research Laboratories), 2017-2025
9.8 Market Value (by Other End User), 2017-2025

10 Global Rare Disease Diagnostics Market (by Region)
10.1 Market Overview (by Region)
10.2 Global Rare Disease Diagnostics Market (by Region)
10.3 Market Value (by Region)

11 North America Rare Disease Diagnostics Market

12 Europe Rare Disease Diagnostics Market

13 Latin America Rare Disease Diagnostics Market

14 Asia Pacific Rare Disease Diagnostics Market

15 MEA Rare Disease Diagnostics Market

16 Company Profiles

  • 23andMe, Inc.
  • 3billion, Inc.
  • BGI
  • Centogene A.G.
  • Eurofins Scientific
  • GENEWIZ
  • Illumina Inc.
  • InDepth Genomics
  • Laboratory Corporation of America
  • Partek, Inc.
  • PerkinElmer, Inc.
  • Personal Genome Diagnostics, Inc.
  • QIAGEN N.V.
  • Retrophin, Inc.
  • Strand Life Sciences Pvt Ltd.

For more information about this report visit https://www.researchandmarkets.com/research/qxjh3k/global_rare?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

CONTACT: 
CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Diagnostics

Ads